Regeneron (REGN), Sanofi (SNY) on 'Last Stretch' of Praluent Development - Roth Capital
Tweet Send to a Friend
Roth Capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) with a Buy rating and price target of $481 and the company nnounced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
